Clinical Trials Browser

Lymphoma × GSK2141795 × Breast × Clear all

NCT00920257 2017-11-13

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

Phase 1 Completed

BreastGynecologicLymphoid

Breast Neoplasms, Lymphoma, Neoplasms, Endometrial Neoplasms